Clinical Trial: A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015242) titled 'A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma' on June 03.

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

Study Start Date: Sept. 30, 2025

Study Type: INTERVENTIONAL

Condition: Lymphoma

Intervention: DRUG: Rituximab

Specified dose on specified days

DRUG: Methotrexate

Specified dose on specified days

DR...